| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.02M | 40.68M | 67.66M | 63.00M | 70.56M | 50.68M |
| Gross Profit | 21.17M | 21.67M | 45.35M | 6.88M | 15.63M | 13.62M |
| EBITDA | -1.83M | 10.48M | -23.72M | 21.93M | 38.07M | 26.47M |
| Net Income | -37.81M | -21.12M | -38.18M | -7.79M | 4.98M | 2.06M |
Balance Sheet | ||||||
| Total Assets | 83.51M | 75.05M | 127.32M | 196.17M | 240.18M | 231.53M |
| Cash, Cash Equivalents and Short-Term Investments | 9.79M | 13.86M | 4.26M | 6.35M | 17.05M | 19.97M |
| Total Debt | 146.85M | 164.99M | 181.60M | 175.86M | 203.62M | 214.58M |
| Total Liabilities | 166.61M | 180.40M | 210.06M | 217.04M | 242.16M | 229.47M |
| Stockholders Equity | -17.03M | -42.35M | -36.35M | 2.18M | 12.32M | 7.07M |
Cash Flow | ||||||
| Free Cash Flow | -9.74M | 24.01M | 34.51M | 6.41M | 14.06M | -6.27M |
| Operating Cash Flow | -3.84M | 24.27M | 35.16M | 9.35M | 30.40M | 20.04M |
| Investing Cash Flow | -5.80M | -250.00K | -644.00K | -2.93M | -16.31M | -26.27M |
| Financing Cash Flow | 37.22M | -11.98M | -34.94M | -19.01M | -19.81M | 15.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
49 Neutral | HK$140.22M | -0.74 | -4.69% | ― | 3.58% | -87.78% | |
49 Neutral | HK$106.54M | 21.02 | 1.89% | ― | -32.86% | ― | |
47 Neutral | HK$146.75M | -2.01 | ― | ― | -16.39% | -10.74% | |
47 Neutral | HK$275.24M | -0.28 | -18.68% | ― | -3.51% | -15.27% | |
47 Neutral | HK$259.20M | -1.76 | -56.32% | ― | -2.19% | 3.63% | |
46 Neutral | HK$51.54M | -3.30 | -1.69% | ― | -4.96% | -332.17% |
Legend Strategy International Holdings Group Co., Ltd. has agreed, through a purchaser subsidiary, to acquire 100% of Auro Hong Kong Limited for HK$22 million, together with a shareholder loan, which will give it an indirect 37.5% equity stake in Beisheng Biotechnology accounted for under the equity method. The deal, classified as a discloseable transaction under Hong Kong listing rules and not requiring shareholder approval, will make Auro Hong Kong an indirect wholly owned subsidiary, potentially expanding Legend Strategy’s exposure to the biotechnology sector, though completion remains subject to conditions and may not proceed, prompting a cautionary note to investors.
The most recent analyst rating on (HK:1355) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on Legend Strategy International Holdings Group Co., Ltd. stock, see the HK:1355 Stock Forecast page.
Legend Strategy International Holdings Group Company Limited plans to rebrand itself as Biosysen Limited, adopting a new English and Chinese company name and logo, subject to shareholder approval at an extraordinary general meeting and confirmation from the Cayman Islands registrar and the Hong Kong Stock Exchange. The company emphasized that the name and logo change, intended to better align with its future business development direction, will not affect shareholders’ rights, daily operations, or its financial position, and existing share certificates will remain valid even as new certificates and the stock short name transition to the new branding once the change takes effect.
The most recent analyst rating on (HK:1355) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on Legend Strategy International Holdings Group Co., Ltd. stock, see the HK:1355 Stock Forecast page.